Ultragenyx subsidiary Amlogenyx to attend Jefferies healthcare conference in London
RARE•Ultragenyx subsidiary Amlogenyx is raising Series A financing to establish Phase 2a proof of concept for its Alzheimer's therapy AM805. Management will hold investor meetings at the Jefferies Global Healthcare Conference in London on November 16-19, 2026.
1. Conference meetings
Management will hold investor meetings at the 2026 Jefferies Global Healthcare Conference in London, November 16-19.
2. AM805 development
Amlogenyx is raising Series A financing to establish Phase 2a clinical proof of concept for AM805, described as a clinic-ready protease therapy shown to reduce amyloid accumulation in preclinical Alzheimer's disease models.
